https://www.selleckchem.com/pr....oducts/vanzacaftor.h
Most patient-reported outcome (PRO) instruments that measure atopic dermatitis (AD) symptoms do not have sufficient documented evidence of content validity to satisfy regulatory agency guidance for inclusion in product-labelling claims in the USA or Europe. The objective of this study was to develop a PRO instrument in accordance with regulatory agency guidance to assess daily AD symptoms during the course of therapy and to establish its content validity and psychometric properties. The Pruritus and Symptoms Assessment for Atopic De
Synes godt om
Kommentar
Del
